
We focus on development of rapid point-of-care diagnostics for infectious diesease detection as well as innovative reagents for diagnostic and therapeutic purposes. Our strength lies in the proprietary technologies for sample preparation, production of monoclonal antibodies targeted primarily to the carbohydrate antigens and improvement of existing technologies used in development of molecular diagnostics. Our expertise in the fields of chemistry and immunology enables us to generate a number of highly sensitive and avid monoclonal antibodies to be used in Tuberculosis diagnostics, as well as…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more